this
Window
Description | File Data | Subject Coverage | Sources | Database Producer | Usage Terms
|
Close this Window |
Description | File Data | Subject Coverage | Sources | Database Producer | Usage Terms |
|
ADISINSIGHT (Adis R&D Insight) contains the full text of reports, i.e., profiles, on drugs in active research and development by the international pharmaceutical industry. New drugs are added to the database when they appear in the earliest laboratory report and are followed through to world market launch. Every scientific or commercial development of the drug's progress to market is assessed, evaluated, and reported. Adis editors check all the information to ensure the integrity and timeliness of the information.
The records in this file contain generic names, synonyms, trade names, CAS Registry Numbers®, EphMRA ATC codes, WHO ATC codes, developing companies, development stages by indication and country, licensed forecast information from Lehman Brothers, and Adis's own unique therapeutic value rating. The text includes an introduction, evaluation, commercial summary, clinical overview, adverse effects, pharmacology with pharmokinetics and pharmacodynamics, and therapeutic trials. Bibliographic references are also included.
Wolters Kluwer Pharma Solutions 770 Township Line Road, Suite 300 Yardley, PA 19067 USA Phone: (877) 872 2347 or 267 757 3421 (ext. 1) Fax: (877) 234 7329 Europe and Asia Pacific: Phone: (+44) 20 7981 0765 Email: clientsupport@wolterskluwer.com
Usage terms for ADISINSIGHT are detailed in the CAS Information Use Policies.
For more detailed information, view the STN Database Summary Sheet.